[{"id":"f7e16369-1429-45d8-9dba-024985674f87","acronym":"","url":"https://clinicaltrials.gov/study/NCT00080886","created_at":"2021-01-18T00:13:28.893Z","updated_at":"2024-07-02T16:35:34.490Z","phase":"Phase 2","brief_title":"Rituximab, Carmustine; Cytarabine, Etoposide, \u0026 Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT00080886","lead_sponsor":"University of Nebraska","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • etoposide IV • carmustine • melphalan • Gliadel Wafer (carmustine implant) • captisol-enabled melphalan"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 05/08/2002","start_date":" 05/08/2002","primary_txt":" Primary completion: 11/01/2005","primary_completion_date":" 11/01/2005","study_txt":" Completion: 03/12/2015","study_completion_date":" 03/12/2015","last_update_posted":"2023-10-06"}]